Difference between revisions of "Gaiser 2019 Adv Ther (Weinh)"
(Created page with "{{Publication |title=Gaiser A, Hafner S, Schmiech M, BĂŒchele B, SchĂ€fer P, Arnim CA, Calzia, E, FeuringâBuske M, Buske C, Vick B, Jeremias I, Syrovets T, Simmet T (2019) G...")  |
 |
||
(3 intermediate revisions by 2 users not shown) | |||
Line 6: | Line 6: | ||
|journal=Adv Ther (Weinh) | |journal=Adv Ther (Weinh) | ||
|abstract=This study explores biocompatible aminoâfunctionalized gold nanoparticles (AuâNH<sup>2</sup>) as nanotherapeutics for the selective eradication of leukemia cells, elucidates the mechanism of cytotoxicity, and it confirms ''in vivo'' efficacy of the engineered nanomaterial. AuâNH<sup>2</sup> trigger apoptotic cell death of myeloid leukemia cell lines and primary acute myeloid leukemia (AML) cells by i) inhibition of mitochondrial respiration, ii) ATP depletion, iii) loss of mitochondrial membrane potential, and iv) mitochondrial release of cytochrome c. AuâNH<sup>2</sup> act selectively on leukemia cells inasmuch as the viability of normal peripheral blood mononuclear cells and macrophages as well as the colony formation of hematopoietic stem cells remain basically unaffected. The selectivity of AuâNH<sup>2</sup> for AML cells can be attributed to both the preferential accumulation of AuNH<sup>2</sup> in AML cells and the strong dependence of those cells on mitochondrial oxidative phosphorylation for ATP production. Importantly, AuâNH<sup>2</sup> applied either as monotherapy or as a cytarabine combination regimen possess antileukemic efficacy in the absence of adverse events in mice xenografted with primary human AML ''in vivo''. The engineered material may pave the way for a novel nanotherapeutic treatment of AML. | |abstract=This study explores biocompatible aminoâfunctionalized gold nanoparticles (AuâNH<sup>2</sup>) as nanotherapeutics for the selective eradication of leukemia cells, elucidates the mechanism of cytotoxicity, and it confirms ''in vivo'' efficacy of the engineered nanomaterial. AuâNH<sup>2</sup> trigger apoptotic cell death of myeloid leukemia cell lines and primary acute myeloid leukemia (AML) cells by i) inhibition of mitochondrial respiration, ii) ATP depletion, iii) loss of mitochondrial membrane potential, and iv) mitochondrial release of cytochrome c. AuâNH<sup>2</sup> act selectively on leukemia cells inasmuch as the viability of normal peripheral blood mononuclear cells and macrophages as well as the colony formation of hematopoietic stem cells remain basically unaffected. The selectivity of AuâNH<sup>2</sup> for AML cells can be attributed to both the preferential accumulation of AuNH<sup>2</sup> in AML cells and the strong dependence of those cells on mitochondrial oxidative phosphorylation for ATP production. Importantly, AuâNH<sup>2</sup> applied either as monotherapy or as a cytarabine combination regimen possess antileukemic efficacy in the absence of adverse events in mice xenografted with primary human AML ''in vivo''. The engineered material may pave the way for a novel nanotherapeutic treatment of AML. | ||
|editor=[[Plangger M]] | |editor=[[Plangger M]] | ||
|mipnetlab=DE Ulm Radermacher P | |mipnetlab=DE Ulm Radermacher P | ||
}} | }} | ||
Line 16: | Line 16: | ||
|preparations=Intact cells | |preparations=Intact cells | ||
|couplingstates=LEAK, ROUTINE, ET | |couplingstates=LEAK, ROUTINE, ET | ||
|pathways=ROX | |||
|instruments=Oxygraph-2k | |instruments=Oxygraph-2k | ||
|additional=Labels, 2019-03, PBMCs | |additional=Labels, 2019-03, Leukemia, PBMCs | ||
}} | }} |
Latest revision as of 14:36, 5 July 2023
Gaiser A, Hafner S, Schmiech M, BĂŒchele B, SchĂ€fer P, Arnim CA, Calzia, E, FeuringâBuske M, Buske C, Vick B, Jeremias I, Syrovets T, Simmet T (2019) Gold nanoparticles with selective antileukemic activity in vitro and in vivo target mitochondrial respiration. Adv Ther (Weinh) doi:10.1002/adtp.201800149. |
» Open Access
Gaiser A, Hafner S, Schmiech M, Buechele B, Schaefer P, Arnim CA, Calzia E, FeuringâBuske M, Buske C, Vick B, Jeremias I, Syrovets T, Simmet T (2019) Adv Ther (Weinh)
Abstract: This study explores biocompatible aminoâfunctionalized gold nanoparticles (AuâNH2) as nanotherapeutics for the selective eradication of leukemia cells, elucidates the mechanism of cytotoxicity, and it confirms in vivo efficacy of the engineered nanomaterial. AuâNH2 trigger apoptotic cell death of myeloid leukemia cell lines and primary acute myeloid leukemia (AML) cells by i) inhibition of mitochondrial respiration, ii) ATP depletion, iii) loss of mitochondrial membrane potential, and iv) mitochondrial release of cytochrome c. AuâNH2 act selectively on leukemia cells inasmuch as the viability of normal peripheral blood mononuclear cells and macrophages as well as the colony formation of hematopoietic stem cells remain basically unaffected. The selectivity of AuâNH2 for AML cells can be attributed to both the preferential accumulation of AuNH2 in AML cells and the strong dependence of those cells on mitochondrial oxidative phosphorylation for ATP production. Importantly, AuâNH2 applied either as monotherapy or as a cytarabine combination regimen possess antileukemic efficacy in the absence of adverse events in mice xenografted with primary human AML in vivo. The engineered material may pave the way for a novel nanotherapeutic treatment of AML.
âą Bioblast editor: Plangger M âą O2k-Network Lab: DE Ulm Radermacher P
Labels: MiParea: Respiration, mt-Medicine, Pharmacology;toxicology
Pathology: Cancer
Organism: Human Tissue;cell: Blood cells Preparation: Intact cells
Coupling state: LEAK, ROUTINE, ET
Pathway: ROX
HRR: Oxygraph-2k
Labels, 2019-03, Leukemia, PBMCs